Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.09 AUD -3.23% Market Closed
Market Cap: 108.1m AUD

Arovella Therapeutics Ltd
Investor Relations

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Michael Baker
CEO, MD & Director
No Bio Available
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D.
Chief Operating Officer
No Bio Available
Mr. Timothy Luscombe B.Com., C.A.
Company Secretary & CFO
No Bio Available
Michelle Long
Administration Manager
No Bio Available

Contacts

Address
WESTERN AUSTRALIA
Perth
Osborne Park, U 12 L 1, 55 Howe St
Contacts
+61861425555.0
www.arovella.com